Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.

Chan DW, Hui WW, Wang JJ, Yung MM, Hui LM, Qin Y, Liang RR, Leung TH, Xu D, Chan KK, Yao KM, Tsang BK, Ngan HY.

Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.

2.

Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis.

Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu M, Feng XH, Sawaya R, Medema RH, Hung MC, Huang S.

J Clin Invest. 2014 Feb;124(2):564-79. doi: 10.1172/JCI71104. Epub 2014 Jan 2.

3.

Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.

Lok GT, Chan DW, Liu VW, Hui WW, Leung TH, Yao KM, Ngan HY.

PLoS One. 2011;6(8):e23790. doi: 10.1371/journal.pone.0023790. Epub 2011 Aug 17.

4.

FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.

Fan Q, Cai Q, Xu Y.

Oncotarget. 2015 Sep 29;6(29):27688-99. doi: 10.18632/oncotarget.4280.

5.

Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Kong X, Li L, Li Z, Le X, Huang C, Jia Z, Cui J, Huang S, Wang L, Xie K.

Cancer Res. 2013 Jul 1;73(13):3987-96. doi: 10.1158/0008-5472.CAN-12-3859. Epub 2013 Apr 18.

6.

FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.

Wang Y, Yun Y, Wu B, Wen L, Wen M, Yang H, Zhao L, Liu W, Huang S, Wen N, Li Y.

Oncotarget. 2016 Jul 26;7(30):47985-47997. doi: 10.18632/oncotarget.10103.

7.

TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC.

Cancer Res. 2013 Aug 15;73(16):5016-28. doi: 10.1158/0008-5472.CAN-13-0023. Epub 2013 Jul 3.

8.

Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.

Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, Yang HW, Deatherage DE, Kuo CT, Huang YW, Yan PS, Hsiao SH, Tai CK, Lin HJ, Davuluri RV, Chao TK, Nephew KP, Huang TH, Lai HC, Chan MW.

Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11.

9.

Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-β signaling pathway.

Chen F, Zhuang M, Peng J, Wang X, Huang T, Li S, Lin M, Lin H, Xu Y, Li J, Chen Z, Huang Y.

Mol Med Rep. 2014 Oct;10(4):1999-2003. doi: 10.3892/mmr.2014.2452. Epub 2014 Aug 5.

PMID:
25109410
10.

Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.

Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR.

Oncotarget. 2015 Sep 29;6(29):27613-27. doi: 10.18632/oncotarget.4546.

11.

TGF-β-activated SMAD3/4 complex transcriptionally upregulates N-cadherin expression in non-small cell lung cancer.

Yang H, Wang L, Zhao J, Chen Y, Lei Z, Liu X, Xia W, Guo L, Zhang HT.

Lung Cancer. 2015 Mar;87(3):249-57. doi: 10.1016/j.lungcan.2014.12.015. Epub 2015 Jan 5.

PMID:
25595426
12.

Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.

Llauradó M, Majem B, Castellví J, Cabrera S, Gil-Moreno A, Reventós J, Ruiz A.

Mol Cancer Res. 2012 Jul;10(7):914-24. doi: 10.1158/1541-7786.MCR-11-0449. Epub 2012 May 15.

13.

Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.

Chan DW, Hui WW, Cai PC, Liu MX, Yung MM, Mak CS, Leung TH, Chan KK, Ngan HY.

PLoS One. 2012;7(12):e52578. doi: 10.1371/journal.pone.0052578. Epub 2012 Dec 20. Erratum in: PLoS One. 2014;9(10):e110304.

14.

Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer.

Yeh KT, Chen TH, Yang HW, Chou JL, Chen LY, Yeh CM, Chen YH, Lin RI, Su HY, Chen GC, Deatherage DE, Huang YW, Yan PS, Lin HJ, Nephew KP, Huang TH, Lai HC, Chan MW.

Epigenetics. 2011 Jun;6(6):727-39. Epub 2011 Jun 1.

15.

Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.

Norita R, Suzuki Y, Furutani Y, Takahashi K, Yoshimatsu Y, Podyma-Inoue KA, Watabe T, Sato Y.

Cancer Sci. 2017 Mar;108(3):419-426. doi: 10.1111/cas.13157.

16.

Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.

Rodgers LH, Ó hAinmhire E, Young AN, Burdette JE.

Oncotarget. 2016 May 31;7(22):32785-95. doi: 10.18632/oncotarget.9051.

17.

The murine gastrin promoter is synergistically activated by transforming growth factor-beta/Smad and Wnt signaling pathways.

Lei S, Dubeykovskiy A, Chakladar A, Wojtukiewicz L, Wang TC.

J Biol Chem. 2004 Oct 8;279(41):42492-502. Epub 2004 Jul 28.

18.

ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer.

Kennedy BA, Deatherage DE, Gu F, Tang B, Chan MW, Nephew KP, Huang TH, Jin VX.

PLoS One. 2011;6(7):e22606. doi: 10.1371/journal.pone.0022606. Epub 2011 Jul 25.

19.

Prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition.

Chaudhry P, Fabi F, Singh M, Parent S, Leblanc V, Asselin E.

Cell Death Dis. 2014 Feb 6;5:e1044. doi: 10.1038/cddis.2014.7.

20.

Antimetastatic role of Smad4 signaling in colorectal cancer.

Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK.

Gastroenterology. 2010 Mar;138(3):969-80.e1-3. doi: 10.1053/j.gastro.2009.11.004. Epub 2009 Nov 10.

Supplemental Content

Support Center